Scientific judgement and execution support for biotech investors
Fewer unknowns. Cleaner answers. Stronger conviction.
Two questions define every early-stage biotech investment: is the science compelling enough to back? And can it actually be delivered? Answering both, rigorously and independently, is where most diligence processes fall short.
Linchpin gives investors an independent view of both: the scientific rigour of the opportunity and the operational reality of executing it. From pre-investment diligence through to portfolio company build-out, we help you make better decisions and protect what comes after them.
The investor reality
The environment has changed.
The risk profile has not.
Early-stage biotech investment has always been defined by incomplete information, compressed timelines, and science too specialised to evaluate without deep domain expertise. VCs are writing fewer cheques, but writing them smarter. The burden of conviction before commitment is higher, and the cost of a misread, scientific or operational, is greater. The challenge is knowing whether the science is real, whether the development pathway is credible, and whether the team can execute it.
Insight without execution clarity creates hidden risk.
The problem
Where investment decisions break down
Scientific conviction and operational readiness need to be tested together. Before investment, unresolved assumptions can obscure programme risk; after investment, gaps in capability and coordination can prevent a strong plan from being delivered.
Pre-investment:
the science is not fully stress-tested
Key scientific risks are not fully surfaced, translational assumptions are not stress-tested, and the development pathway is not clearly defined.
Post-investment:
the team cannot execute the plan
Portfolio companies may have a credible plan but lack the operational depth to execute it: specialist capability gaps, fragmented CRO relationships and unclear delivery accountability can slow progress towards the next milestone.
Pre-investment
Independent scientific diligence
The technical team assembled for each engagement is matched to the science and the opportunity, not a generalist panel, but specialists chosen for the biology, the modality, and the stage. The assessment covers the questions that matter. Beyond reviewing data, the goal is to assess whether the programme has a credible and executable path forward.
Discuss diligence supportWhat this enables at investment committee
We help you walk into IC with fewer unknowns and cleaner answers: better-informed discussion, stronger conviction, and early identification of the gaps that need addressing before or after investment.
Direct IC support is available: presenting findings, fielding technical questions, helping your partners interrogate the science with confidence.
The Linchpin Review
Independent programme assessment
Go / Fix / Kill: the output you receive
The Linchpin Review is a structured rapid assessment that delivers clear Go / Fix / Kill signals for any drug development programme, whether you are an investor seeking an independent view of a portfolio asset, or a management team that wants rigorous, external scrutiny before a board presentation or financing.
The Red Team Assessment
An optional Red Team Assessment is available: a structured ‘friendly opposition’ exercise in which a separate Linchpin team challenges the programme’s core assumptions from first principles.
Post-investment execution risk
Supporting portfolio company build and execution
Many portfolio challenges emerge after the cheque is written, not before. Linchpin works alongside portfolio companies to bridge capability gaps and drive execution. Think of it as a portfolio science engine: the right expertise, in the right form, for exactly as long as the programme requires it. We can support across the full Concept to Clinic continuum.
Explore portfolio supportHow we operate within portfolio companies
-
Embedded within the portfolio team
Not parachuted in as an external layer -
Flexible deployment
Fractional, project-based, or ongoing as the programme evolves -
Integrated across scientific and operational domains
Single point of coordination -
Milestone-driven and capital-efficient
Single contract, single invoice
Continuity
Continuity from diligence to delivery
The gaps identified at diligence too often become the programme risks that emerge twelve months later.
The Linchpin lifecycle
PRE-INVESTMENT
Independent scientific diligence: risks, gaps, IC preparation
AT INVESTMENT
Development strategy and R&D plan aligned to the financing
POST-INVESTMENT
Embedded execution support, programme build-out, CRO management, milestone delivery
Why Linchpin
A structural distinction, not a claimed one.
Independence here is structural. It is the absence of the conflicts that make most advisors unreliable in the diligence room.
-
Independent
No CRO, platform, or investment bias. -
Operators
Experienced in real-world drug development, not career consultants. -
Integrated
Cross-disciplinary expertise coordinated as one team. -
Execution-focused
The same team that assesses a programme can execute it. -
Flexible
Adapting to investment stage, portfolio complexity, and the specific gaps that need filling. -
Already working with investors
Experienced in running programmes for funds at the scale you operate at, across the US, Europe and Asia.
Strengthen your investment decisions and portfolio execution
Whether you are evaluating a new opportunity or strengthening execution in an existing portfolio company, Linchpin provides both independent scientific judgement and operational capability you can trust, from the first diligence conversation to the last milestone before your next IC. Let’s talk.